# US 6,730,706 B2 · Treatments using venlafaxine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,706 B2
- Document ID: US6730706B2
- Status: Granted
- Kind: B2
- Application number: 10/396,043
- Filed: 2003-03-25
- Published: 2003-09-25
- Granted: 2004-05-04
- Earliest claimed: 1993-06-28
- Assignees: Wyeth
- Inventors: Richard L. Rudolph; G. Virginia Upton
- Web page: https://patentgrep.com/patent/US6730706B2

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase dysphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: in which A is a moiety of the formula where the dotted line represents optional unsaturation; R1 is hydrogen or alkyl; R2 is alkyl; R4 is hydrogen, alkyl, formyl, or alkanol; R5 and R6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method of treating late luteal phase dysphoric disorder in a mammal, comprising administering to the mammal an effective amount of a compound of the formula:
in which A is a moiety of the formula
wherein
the dotted line represents optional unsaturation;
R1 is hydrogen or alkyl of 1 to 6 carbon atoms;
R2 is alkyl of 1 to 6 carbon atoms;
R4 is hydrogen, alkyl of 1 to 6 carbon atoms, formyl, or alkanol of 2 to 7 carbon atoms;
R5 and R6 are, independently, hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, cyano, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group is of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo, trifluoromethyl, or taken together, methylene dioxy;
R7 is hydrogen or alkyl of 1 to 6 carbon atoms; and
n is 0, 1, 2, 3, or 4;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1 wherein the mammal is a human.

### Claim 3 (depends on 1)

The method of claim 1 wherein the composition is administered orally.

### Claim 4

A method of treating late luteal phase dysphoric disorder in a mammal, comprising administering to the mammal a pharmaceutical composition comprising an effective amount of a compound of the formula:
in which A is a moiety of the formula
wherein
the dotted line represents optional unsaturation, and
R1 is hydrogen or alkyl of 1 to 6 carbon atoms;
R2 is alkyl of 1 to 6 carbon atoms;
R4 is hydrogen, alkyl of 1 to 6 carbon atoms, formyl, or alkanol of 2 to 7 carbon atoms;
R5 and R6 are, independently, hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, cyano, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group is of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo, trifluoromethyl, or taken together, methylene dioxy;
R7 is hydrogen or alkyl of 1 to 6 carbon atoms; and
n is 0, 1, 2, 3, or 4;
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 5 (depends on 4)

The method of claim 4 wherein the compound is:
in which A is a moiety of the formula
wherein
the dotted line represents optional unsaturation, and
R1 is hydrogen or alkyl of 1 to 3 carbon atoms;
R2 is alkyl of 1 to 3 carbon atoms;
R5 is hydrogen, hydroxyl, alkoxy of 1 to 3 carbon atoms, chloro, bromo, trifluoromethyl or alkyl of 1 to 3 carbon atoms;
R6 is alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms, chloro, bromo, trifluoromethyl or alkanoyloxy of 2 to 3 carbon atoms;
R7 is hydrogen or alkyl of 1 to 3 carbon atoms;
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The method of claim 1 wherein R5 and R6 are both in the meta positions or one of R5 or R6 is in the para position and n is 2.

### Claim 7 (depends on 1)

The method of claim 1 wherein the compound is 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The method of claim 1 wherein the compound is 1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

The method of claim 1 wherein the effective amount comprises a daily dose of between about 50 mg/day and about 375 mg/day.

### Claim 10 (depends on 1)

The method of claim 1 wherein the effective amount comprises a daily dose of between about 75 mg/day and about 200 mg/day.

### Claim 11 (depends on 1)

The method of claim 1 wherein the mammal is a human.

### Claim 12 (depends on 1)

The method of claim 1 wherein the pharmaceutical composition is administered orally.

### Claim 13 (depends on 1)

The method of claim 1 wherein the pharmaceutical composition is in a unit dosage form which is a tablet.

### Claim 14 (depends on 1)

The method of claim 1 wherein the pharmaceutical composition is in a unit dosage form which is a capsule.
